Overview
Voyager Acquisition Corp. and Veraxa Biotech AG Announce Business Combination
07. May 2025
Bratschi represented Voyager Acquisition Corp., a publicly traded Cayman Islands Special Purpose Acquisition Company (SPAC), on Swiss law related aspects concerning its announced business combination agreement with Zurich-based Veraxa Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies.
The combination will result in Veraxa Biotech AG becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a valuation of approximately USD 1.64 billion. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals.
The Bratschi team was led by Claudio Bazzi (Partner, Corporate/M&A) and included Marco Rizzi (Partner, Corporate/M&A), Michael Barrot (Partner, Tax), Adrian Bieri (Partner, IP), Felix Kesselring (Partner, Life Sciences), Daniel Mosimann (Associate, Corporate/M&A), Stephanie Caprani-Pontes (Associate, Corporate/M&A) and Rico Dufner (Associate, Tax).
People
Michael Alexis Barrot
To profile
Attorney-at-Law,
Partner,
Certified Tax Expert
Head Taxation
Zurich
Claudio Bazzi
To profile
Attorney-at-Law,
Partner,
Member of the Board of Directors
Co-Head Sports
Zurich
Adrian Bieri
To profile
Attorney-at-Law,
Partner
Head Intellectual Property, Technology and Data Protection
Zurich
Felix Kesselring
To profile
Attorney-at-Law,
Partner
Head Pharmaceuticals and Healthcare
Zurich
Marco A. Rizzi
To profile
Attorney-at-Law,
Partner
Co-Head International Practice
Zurich, Geneva
News
11.11.2025
Learn more
Bratschi Advises the Sellers of Rugenbräu AG on Succession Planning
The two members of the management board of Rugenbräu AG, Remo Kobluk (CEO) and Christian Schneiter (CFO), are taking over the traditional brewery in the canton of Berne together with Bernese entrepreneur Bernard Fuhrer, owner and managing director of Brauerei Felsenau AG, and Dominique Gottret, a Bernese lawyer. This means that Rugenbräu AG remains in Bernese hands, supported by individuals who have known the company for years and have close ties to it.
06.11.2025
Learn more
Bratschi represents the University Hospital Basel in the takeover of the Claraspital Basel in merger control proceedings before COMCO
The University Hospital Basel will take over the Claraspital Basel and the other companies of the Clara Group. Thereby, one of the three largest university hospitals in Switzerland will be formed.
The Swiss Competition Commission (COMCO) has examined the takeover and has decided not to initiate main proceedings. This means that the Claraspital can be integrated into the Group of the University Hospital Basel. The planned Comprehensive Cancer Center, where oncological services will be bundled at the site of the Claraspital, will provide Northwestern Switzerland with cutting-edge care in the field of cancer.
Bratschi advised and represented the University Hospital Basel in the merger proceedings before the COMCO. The Bratschi team was led by Prof Dr Rolf H. Weber (Competition) and encompassed Dr Samuel Jost and Dr Claudia Walz (both Competition).
30.10.2025
Learn more
IFLR1000-Ranking 2025
Bratschi freut sich sehr über die Anerkennung in den diesjährigen IFLR1000-Rankings – sowohl auf kollektiver Ebene als Kanzlei als auch durch die individuellen Auszeichnungen unserer engagierten Anwältinnen und Anwälte.
Diese Platzierungen unterstreichen unser kontinuierliches Bestreben, unseren Klientinnen und Klienten höchste Qualität und Fachkompetenz in allen Bereichen des Wirtschaftsrechts zu bieten.
Ein herzliches Dankeschön an unser gesamtes Team für die hervorragende Arbeit und das tägliche Engagement – und Gratulation an alle, die in diesem Jahr ausgezeichnet wurden!
Always stay up to date
Subscribe to the Bratschi newsletter